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Abstract. There is strong epidemiologic evidence indicating 
that common genetic variability could be implicated in pancre-
atic cancer risk and, to date, various loci have been proposed. 
In particular, there is increasing evidence of the involvement 
of ABO gene variability and pancreatic cancer risk. In a large 
multicentric study of 1,028 pancreatic ductal adenocarcinoma 
cases and 2,257 controls in the context of the PANcreatic 
Disease ReseArch (PANDoRA) consortium, we investigated 
the suggested association with increased risk for carriers of 
single nucleotide polymorphisms (SNPs) determining the A 
or B allele in comparison with the O allele, which encodes for 
a non-functional enzyme. Since glycosyltransferase activity, 
encoded by ABO, is higher for the A1 variant compared with 
the A2 variant, we investigated the hypothesis that A1 carriers 
were at an increased risk of pancreatic cancer. In our analysis, 
carriers of the A1 were indeed at greater risk of developing the 
disease. In addition, we investigated the possible influence that 
genetic variability at the ABO locus may have in pancreatic 
cancer survival, but we observed no effect in our population.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-related 
mortality in the European Union and in the USA, with a 5-year 
survival of less than 5% (1). The latter applies particularly for 
pancreatic ductal adenocarcinoma (PDAC), the most common 
form of the disease. There is no effective screening test for 
pancreatic cancer and metastatic disease is commonly present 
at initial diagnosis. Established risk factors include cigarette 
smoking, obesity, a medical history of diabetes type II and 
family history of pancreatic cancer (2,3). Moreover, it has 
been shown that a small proportion of pancreatic tumors arises 
as a result of high penetrance germline mutations in genes 
such as BRCA1, BRCA2, p16/CDKN2A, STK11/LKB, APC, 
PRSS1, SPINK, KRAS and PALB2 (2-5). However, the very 
low frequency of those mutations cannot explain the bulk of 
genetic susceptibility to pancreatic cancer.
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There is strong epidemiologic evidence indicating that 
common genetic variability could be implicated in the disease 
risk and various risk loci have been proposed. Three genome-
wide association studies have been performed and resulted in 
several loci convincingly being associated with risk of pancre-
atic cancer (6-9). In particular, there is increasing evidence of 
the involvement of the ABO gene variability and pancreatic 
cancer risk (6,10-12).
The ABO gene encodes enzymes known as glycosyltrans-
ferases which transfer specific sugar residues to a precursor 
substance (the H antigen) to produce the A and B antigens. 
Glycosylation is one of the most prevalent modifications 
mediated by complex enzymatic machinery, whereby glycans 
(sugars) are covalently attached to specific amino acid sites 
of proteins. Glycans have key biological functions in protein 
maturation and turnover, cell adhesion and trafficking and 
receptor binding and activation (13).
There are three major alleles at the ABO locus on 
chromosome 9q34: alleles A, B and O, defined by single 
base deletions and substitutions (single nucleotide poly-
morphisms; SNPs) occurring in exons 6 and 7. The A allele 
encodes α1→3 N-acetylgalactosaminyltransferase, which adds 
N-acetylgalactosamine (GalNAc) to the H antigen to form the 
A antigen. The B allele encodes α1→3 galactosyltransferase, 
which transfers galactose (Gal) to the H antigen to construct 
the B antigen (14). The O allele does not produce an active 
enzyme (14). Four SNPs at nucleotides (nt) 526, 703, 796 
and 803 resulting in amino acid substitutions (Arg176Gly, 
Gly235Ser, Leu266Met and Gly268Ala) explain all the differ-
ences in the activity and the nucleotide-sugar donor specificity 
of the A and B transferases. In addition, a base substitution 
(rs1053878) at nt 467, resulting in an amino acid substitution 
(proline to leucine), distinguishes the A1 from A2 subtypes. 
A2 is present in approximately 20% of subjects with A blood 
group among Caucasians and shows an intermediate pheno-
type, between the ‘full’ enzymatic activity defined by the A1 
allele and the nonfunctioning enzyme defined by the O allele 
(11,12). The carriers of the A or B allele show an increased 
risk of pancreatic cancer (11,12). A small number of studies 
have also tested the genetic variability of the locus with the 
aggressiveness of the disease and survival of patients, with 
inconsistent results (15-17).
In this large multicentric study of 1,028 pancreatic cancer 
cases and 2,257 controls, we replicated the previously reported 
associations and we also investigated the possible influence 
of the genetic variability at the ABO locus on survival of 
patients with pancreatic cancer, considering also the polymor-
phism discriminating the A1 and A2 variants. Moreover, we 
performed stratified analysis considering the tumor stage in 
order to verify whether genetic variability could be involved 
in the disease prognosis.
Materials and methods
Study population. The study population was described in detail 
elsewhere (18,19). Briefly, 1,028 PDAC cases and 2,257 controls 
were collected retrospectively in five European countries in 
the context of the PANcreatic Disease ReseArch (PANDoRA) 
consortium (18). All cases were collected between 1996 and 
2011. The cases included in the consortium population are 
defined by a confirmed diagnosis of PDAC. For each patient, 
information about gender and age at diagnosis was collected. 
Detailed information concerning overall survival (OS) was 
registered as well.
Comprehensive information on the control population was 
previously provided (18,19). Briefly, a total of 2,121 healthy 
controls of German, Italian, Czech and Polish origin were 
respectively recruited at the Institute of Transfusion Medicine, 
Mannheim, Germany; at the Azienda Ospedaliero-Universitaria 
Meyer (A.O.U. Meyer) Ospedale Pediatrico, Florence, Italy; at 
the Department of Molecular Biology of Cancer, Institute of 
Experimental Medicine, Academy of Science of the Czech 
Republic and First Faculty of Medicine, Charles University in 
Prague, Czech Republic; and at the Department of Hematology, 
Medical University, Lodz, Poland. British controls (N=136) 
were selected from healthy volunteers recruited from the 
general population in two cohorts in the European Prospective 
Investigation on Cancer (EPIC), an ongoing prospective cohort 
being carried out in ten European countries. The EPIC-Norfolk 
cohort (http://www.srl.cam.ac.uk/epic/) comprises >30,000 
individuals, aged 45-75 years at recruitment, residents in 
Norfolk, East Anglia, UK, and recruited from general prac-
tice registers between 1993 and 1997 (20). The EPIC-Oxford 
cohort comprises 65,429 people aged ≥20 years and living in 
the UK, recruited between 1993 and 1999 (21). Characteristics 
of patients and controls are provided in Table I.
Selection of genes and polymorphisms. We examined six SNPs 
on the ABO gene: rs505922, which marks the O allele (11,12), 
rs8176747, rs8176720, rs8176741, rs8176746, which discriminate 
between allele A and B, and rs1053878, which distinguishes 
between the A1 and A2 alleles. These SNPs account for all the 
functionally relevant variability at the ABO locus and predict 
the ABO blood groups, as shown in Table II.
DNA extraction and genotyping. DNA was extracted from 
whole blood or from frozen or paraffin-embedded pancre-
atic tissues of patients and controls using the Qiagen-mini 
kit (Qiagen, Hilden, Germany) or the AllPrep Isolation kit 
(Qiagen) according to the manufacturer's protocol. Genotyping 
was performed using an allele-specific PCR-based KASPar 
SNP genotyping system (KBiosciences, Hoddesdon, UK) 
as recommended by the manufacturer. The order of DNAs 
from cases and controls was randomized on PCR plates 
in order to ensure that an equal number of cases could be 
analyzed simultaneously. Detection was performed using 
an ABI PRISM 7900 HT sequence detection system with 
SDS 2.2 software (Applied Biosystems, Foster City, CA, 
USA). Genotyping for British controls was performed in the 
context of a genome-wide association study using the Human 
660W-Quad BeadChip array according to manufacturer's 
instructions (Illumina, San Diego, CA, USA).
Statistical analysis. Hardy-Weinberg equilibrium was tested 
in the controls by the χ2 test. We used logistic regression for 
multivariate analyses to assess the main effects of the genetic 
polymorphisms on pancreatic cancer risk using a co-dominant 
inheritance model. The most common allele in the controls 
was assigned as the reference category. All analyses were 
adjusted for age, gender and country.
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For survival analysis, the median follow-up time was 
computed with censored observations only, whereas the 
median survival time was calculated using data from all 
patients. OS was defined as the time interval between diagnosis 
and death (uncensored observation) or the last date when the 
patient was still alive (censored observation, mean follow-up 
time 543 days). OS was evaluated using methods for censored 
survival time. In particular, risk of mortality was estimated by 
hazard ratios (HR) and 95% confidence intervals (CI) in Cox 
proportional hazard models. All the analyses were performed 
with STATA software (StataCorp., College Station, TX, USA).
Results
In this study, we investigated two endpoints: i) to replicate 
the associations between 6 ABO SNPs, predictive of the ABO 
blood groups, and the risk of developing pancreatic cancer; 
and ii) to evaluate the possible associations between the same 
SNPs and patient survival.
We carried out genotyping in 1,029 cases and 2,280 
controls. Samples of 1 case and 23 controls were excluded 
due to low call rates (<5 SNPs successfully genotyped), 
therefore we performed statistical analyses on 1,028 cases and 
2,257 controls. The average call rate of the SNPs was 96.78% 
(range 94.48-99.13%). For 27 cases, both normal and tumor 
tissues were available and used for genotyping. No differ-
ences were observed (398 informative genotype comparisons). 
Approximately 15% of the samples were analyzed in duplicate 
and the concordance rate of the genotypes was >99%. In 
controls, the genotype distributions at all loci were within the 
Hardy-Weinberg equilibrium, with non-significant χ2 values 
(data not shown).
By examining all the SNPs separately in relation to 
pancreatic cancer risk, we found that rs8176741, rs8176746 and 
rs8176747 were associated with decreased risk of pancreatic 
cancer, while rs505922 was associated with increased risk 
of developing the disease. The association of this SNP with 
pancreatic cancer risk was previously evaluated in a subgroup 
of the patients of this study and has already been reported (19). 
The remaining two SNPs (rs1053878 and rs8176720) were not 
associated with pancreatic cancer risk. The strongest asso-
ciation observed was that with the T allele of the rs8176741 
SNP (ORhet=0.73; 95% CI 0.58-0.90; ORcarriers=0.75; 95% CI: 
0.60-0.92). The corresponding frequencies and distribution of 
the genotypes and the odds ratios for the association of each 
polymorphism with PDAC risk are summarized in Table III. 
We estimated the risk of pancreatic cancer according to geno-
type-derived ABO blood type among all the study participants, 
as shown in Table IV. For 1,035 German controls, information 
on ABO status, defined serologically (O, A, AB or B), was 
collected at recruitment. In 99.3% of subjects (1,028/1,035), the 
serological blood type and the genotype-derived blood type 
were identical; this proportion strongly supports the accuracy 
of the genotype-defined blood group alleles.
In comparison to individuals with O blood type, those with 
A blood type were at greater risk of developing pancreatic 
cancer (OR 1.24; 95% CI 1.04-1.48). Individuals with B or 
AB blood types did not show any increase in risk. To address 
the hypothesis raised by Wolpin et al (12) that the A1 allele 
confers a greater risk of pancreatic cancer than the A2 allele, 
we estimated ORs for A1 and A2 alleles compared with O, 
which was considered as the reference category. By considering 
all the study population together we observed that individuals 
with genotype A2/O had OR 1.14 (95% CI 0.84-1.54), genotype 
A2/A1 had OR 1.76 (95% CI 1.08-2.89), genotype A1/O had 
OR 1.28 (95% CI 1.06-1.56) and genotype A1/A1 had OR 1.68 
(95% CI 1.14-2.30). Only 2 cases and 7 controls inherited an 
A2/A2 genotype, severely limiting our ability to accurately 
assess risk for subjects with this genotype. These analyses 
are shown in Table IV. When performing subgroup analysis 
according to country of origin we had comparable results (data 
not shown).
Table II. ABO gene SNP selection.
 Blood group
 -------------------------------------------------------------------------------------------
cDNAa aab SNP Tagc O A1 A2 B -------------------------------------------------------------------------------------------
     aa aa aa
261   87 rs8176719 rs505922 del (frame shift)
293   99 rs8176720   gly gly gly
467 156 rs1053878   pro leu pro
526 176 rs7853989 rs8176746  arg arg gly
657 219 rs8176741   his his his
703 235 rs8176743 rs8176746  gly gly ser
796 266 rs8176746   leu leu met
803 268 rs8176747   gly gly ala
930 268 rs8176749 rs8176746  leu leu leu
aPosition (nucleotide number) within the ABO cDNA. bPosition (amino acid/codon number) within the ABO protein. cSNP that can be used as 
surrogate due to high linkage disequilibrium (r2>0.95 in HapMap CEU subjects).
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Table III. Associations between individual ABO SNPs and risk of PDAC.
SNP Genotype Casesa Controlsa ORb (95% CI)b P-value Ptrend
rs8176720 AA 463   974    0.168
 AG 445 1003 0.97 (0.82-1.14) 0.693
 GG 111   275 0.84 (0.65-1.1) 0.205
 AG+GG   0.94 (0.8-1.1) 0.443
rs8176741 CC 845 1689    0.009
 CT 148   400 0.73 (0.58-0.9) 0.004
 TT   12     27 1.07 (0.52-2.19) 0.861
 CT+TT   0.75 (0.6-0.92) 0.006
rs8176746 CC 856 1820    0.068
 CA 158   412 0.80 (0.65-0.99) 0.04
 AA   11   25 1.03 (0.49-2.15) 0.948
 CA+AA   0.81 (0.66-1) 0.049
rs8176747 GG 857 1697    0.027
 CG 160   405 0.77 (0.63-0.95) 0.017
 CC   11   24 1.03 (0.48-2.18) 0.946
 CG+GG   0.79 (0.64-0.97) 0.022
rs505922 TT 342   860    0.026
 CT 518 1055 1.18 (0.99-1.4) 0.066
 CC 163   336 1.19 (0.94-1.51) 0.147
 CT+CC   1.18 (1-1.39) 0.048
rs1053878 AA      0.538
 AG 866 1957 1.05 (0.84-1.33) 0.659
 GG 140   285 0.58 (0.12-2.72) 0.486
 AG+GG     2     9 1.04 (0.83-1.31) 0.741
aNumbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping 
were resubmitted to up to two additional rounds of genotyping. Data points that were still not filled after this procedure were left blank. bOR, odds 
ratio; CI, confidence interval. All analyses were adjusted for age, gender and nationality. Significant associations (p<0.05) are reported in bold.
Table IV. Associations between blood types determined by 6 SNPs in the ABO gene and risk of PDAC.
Blood group Casesa Controlsa ORb (95% CI)b P-value Ptrend
O  343 870 1 (ref) - - 0.895
A  515 968 1.30 (1.09-1.54) 0.003
 A1/O 317 611 1.25 (1.02-1.51) 0.028
 A1/A1   69 112 1.57 (1.11-2.23) 0.011
 A1/A2   32   51 1.71 (1.04-2.80) 0.033
 A2/O   89 187 1.10 (0.82-1.49) 0.517
 A2/A2     2     7 0.79 (0.16-3.87) 0.769
B  120 295 1.04 (0.80-1.35) 0.764
AB   48 142 0.79 (0.54-1.14) 0.208
aNumbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping 
were resubmitted to up to two additional rounds of genotyping. Data points that were still not filled after this procedure were left blank. bOR, odds 
ratio; CI, confidence interval. All analyses were adjusted for age, gender and nationality. Significant associations (p< 0.05) are reported in bold.
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To address the hypothesis that ABO blood groups may also 
have prognostic significance, we analyzed the SNPs and the 
resulting blood groups in relation to patient survival. We found 
no evidence that genetic variability at this locus modifies 
the survival of pancreatic cancer, when taking into account 
multiple testing. We performed stratified analysis considering 
country of origin and TNM status and we observed no statisti-
cally significant association (data not shown). The results of 
the analysis on the whole consortium are shown in Table V.
Discussion
Pancreatic cancer is among the most aggressive types of 
cancer, with mortality rates approaching incidence rates 
(1,22,23). There is currently no effective curative treatment 
for pancreatic cancer. Surgery offers the best treatment option 
and together with some chemotherapeutic treatments it signifi-
cantly improves survival. Finding genetic variants associated 
with disease risk is therefore of the utmost importance to define 
population subgroups who are at high risk of developing the 
disease. Furthermore, identification of genetic factors associ-
ated with progression and survival can significantly contribute 
to identifying patients with better prognosis and may therefore 
help clinicians in the choice of treatment options. As there 
are few known risk factors, improved diagnostics and a better 
understanding of the molecular pathogenesis of this disease 
are urgently needed.
In this study, we investigated two endpoints related to ABO 
glycosyltransferase activity in 1,028 cases and 2,257 controls 
recruited in the context of the PANDoRA consortium. ABO 
Table V. Associations between ABO SNPs and blood types and overall survival of PDAC patients.
SNP or blood group Analysis Subjectsa Deathsa HRb 95% CIb P-value
rs8176720 Per allele 937 761 0.94 (0.84-1.05) 0.264
 AA vs. AG   0.91 (0.78-1.06) 0.240
 AA vs. GG   0.91 (0.72-1.15) 0.440
 AA vs. (AG+GG)   0.91 (0.79-1.05) 0.213
rs8176741 Per allele 922 749 0.82 (0.68-0.99) 0.036
 CC vs. CT   0.79 (0.64-0.98) 0.032
 CC vs. TT   0.81 (0.44-1.52) 0.521
 CC vs. (CT+TT)   0.79 (0.65-0.97) 0.027
s8176746 Per allele 941 768 0.86 (0.72-1.03) 0.100
 CC vs. CA   0.86 (0.70-1.05) 0.139
 CC vs. AA   0.76 (0.39-1.48) 0.422
 CC vs. (CA+AA)   0.85 (0.70-1.03) 0.105
rs8176747 Per allele 944 769 0.85 (0.71-1.02) 0.077
 GG vs. CG   0.85 (0.69-1.04) 0.105
 GG vs. GG   0.76 (0.39-1.47) 0.416
 GG vs. (CG+GG)   0.84 (0.69-1.02) 0.079
rs505922 Per allele 939 763 0.98 (0.83-1.15) 0.797
 TT vs. CT   1.06 (0.85-1.31) 0.610
 TT vs. CC   1.00 (0.86-1.16) 0.971
 TT vs. (CT+CC)   1.02 (0.92-1.13) 0.724
A  924 749 1.04 (0.89-1.22) 0.604
B    0.86 (0.67-1.10) 0.234
AB    0.90 (0.62-1.30) 0.577
aNumbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of 
genotyping were resubmitted to up to two additional rounds of genotyping. Data points that were still not filled after this procedure were left 
blank. bHR, hazard ratio; CI, confidence interval. No association remained statistically significant when multiple testing was taken into account. 
All analyses were adjusted for age, gender, TNM stage and nationality.
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blood group antigens are found in several tissues and in 
particularly great abundance on epithelial cells. They repre-
sent terminal glycosylation steps of glycoproteins or glycolipid 
(24). Glycoconjugates, such as the ABO antigen, are important 
mediators of intercellular adhesion and membrane signaling, 
which are both critical for the progression and spread of 
malignant cells (25). Moreover, as cell surface molecules they 
are also recognized by the host immune response and may 
influence immunosurveillance for malignant cells (26).
Initially, we evaluated the impact of functional genetic 
polymorphisms on pancreatic cancer risk. We observed that 
the minor allele of three SNPs (rs8176741, rs8176746 and 
rs8176747) was associated with decreased risk of pancreatic 
cancer while rs505922 was associated with increased risk of 
developing the disease. The remaining two SNPs did not show 
any association. Polymorphisms rs8176741, rs8176746 and 
rs8176747 are in high linkage disequilibrium in our population 
(mean r2=0.95) and therefore reflect the same association. We 
typed all of them to have a complete assessment of the pheno-
types. By estimating the risk of pancreatic cancer according 
to the blood type we found that only carriers of the A allele 
were at increased risk of the disease, while carriers of the 
B allele were not. This finding is significant considering the 
fact that Wolpin et al reported an increase of risk for carriers 
of A or B allele compared to O carriers (10-12). This is not 
due to lack of statistical power in our study; we had more 
than 87% power to replicate the association with the AB group 
and more than 99% for the B group. Our study and the study 
by Wolpin et al have comparable sizes and the frequencies of 
the ABO alleles are similar in the controls, while they differ 
slightly in the cases (the frequency of AB was 15% in PanScan 
and 10% in PANDoRA). The discrepancy in the results could 
be explained by the fact that PanScan individuals were drawn 
from prospective cohort studies, while PANDoRA subjects 
were collected from case control studies. Divergent results in 
cohort and case control studies have already been reported 
for pancreatic cancer. An example is the association of Sonic 
Hedgehog (SHH) polymorphisms, associated with increased 
pancreatic cancer risk in the PanScan prospective cohorts but 
not in the PanScan case-control studies (6,8).
Wolpin et al (11) suggested that the association of pancre-
atic cancer with the A allele appears to be predominantly due 
to the A1 glycosyltransferase, which exhibits higher activity 
than A2 glycosyltransferase (13). In our analysis, indeed, the 
less efficient enzyme A2 did not increase the disease risk in 
comparison with the non-active O glycosyltransferase.
The results of these two large studies taken together offer 
a strong direct link between the ABO glycosyltransferase 
activity and the pathogenesis of pancreatic cancer and suggest 
that ABO status is not only a marker for pancreatic cancer 
risk but an actual causative factor for developing the disease. 
The latter hypothesis remains to be confirmed by functional 
studies. Since risk factors may also have prognostic signifi-
cance for pancreatic cancer, as suggested (27), we addressed 
the hypothesis that ABO blood types and the genetic vari-
ability at the locus could be implicated in patient survival. To 
date, this has been examined only in studies with a smaller 
sample size than ours (16,17) with inconsistent results. The 
samples from Germany partially overlap with those used 
in a recent study (28). Due to the lack of information on 
CA19-9, lymph node status and grading, we were not able to 
replicate the statistically significant (0.037) association they 
found using a multivariate analysis. In the univariate analysis, 
neither study found any statistically significant effect of ABO 
on survival.
In conclusion, we have confirmed the association of the 
A blood group with increased risk of pancreatic cancer and we 
have shown that the risk is mainly due to the A1 allele, estab-
lishing a direct connection between the enzymatic activity and 
the increased risk.
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